As studies conducted in NPC-positive cell lines have shown, NF-κB inhibitors lead to EBV reactivation and subsequent cell death. LMP1 is an activator of NF-κB signaling in NPC, and as reserchers have shown, high expression of this oncoprotein is observed in 25.7% of cases [68]. This evidence concerns the gene NFKB1 and nasopharyngeal carcinoma.